Abstract
Background: Angiogenesis plays an important role in endometrial carcinogenesis. We reviewed our experience with the anti-VEGF monoclonal antibody bevacizumab for the treatment of recurrent uterine neoplasms. Patients and Methods: A retrospective analysis of women with recurrent uterine neoplasms treated with bevacizumab was performed. Results: A total of 11 patients were identified, 9 with epithelial endometrial carcinomas and 2 with leiomyosarcomas. All patients had multi-site disease and were heavily pretreated with a median of 3 prior chemotherapy regimens. All received bevacizumab combination therapy which was well-tolerated. Two patients had partial responses, 3 had stable disease, while 5 patients progressed. One subject was not assessable for response. The median progression-free interval was 5.4 months for the entire cohort and 8.7 months for those who achieved clinical benefit (PR or SD). Conclusion: Bevacizumab was well-tolerated and displayed promising anti-neoplastic activity in patients with endometrial cancer and uterine leiomyosarcoma.
| Original language | English |
|---|---|
| Pages (from-to) | 3525-3528 |
| Number of pages | 4 |
| Journal | Anticancer research |
| Volume | 27 |
| Issue number | 5 B |
| State | Published - Sep 2007 |
Keywords
- Angiogenesis
- Bevacizumab
- Endometrial cancer
- Uterine cancer